Clinical Trial Update: Second-line Immunotherapy for ES-SCLC [NA]

View source ↗

Summary

A second-line immunotherapy trial (NCT06853678) for extensive-stage small cell lung cancer is currently recruiting at Tianjin Medical University Cancer Institut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC) | NA | Status: RECRUITING